Skip to Content

FDA Approves Risperdal

Risperdal Approved for Schizophrenia, Bipolar Mania

Risperdal is a psychotropic agent indicated for the treatment of schizophrenia, and for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder.

Posted: December 1993

Related Articles:

Risperdal (risperidone) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.